Clinical Trial Update: A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

A Phase 2, single-arm multicenter clinical trial evaluating a triplet regimen of mezigdomide, carfilzomib, and dexamethasone (480Kd) in relapsed or refractory m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Mezigdomide (mezigdomide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Status: NOT_YET_RECRUITING